Cerep operates in the Commercial physical research sector. Cerep SA is a France-based company that specializes in the pre-clinical research, discovery and development of new pharmaceutical drugs. The Company, using its BioPrint technology systems that analyzes pharmaceutical drugs on the market, those that have been withdrawn, and those that failed in the development stages, builds up predictive models of the potential of new drugs. These predictions are based on the drugs' chemical structure and their performance in vitro. The Company then offers solutions to the pharmaceutical and biotechnology sectors on reducing time and costs in the early stages of the drug development process. Clients can also gain access to some of the Company's technology by subscribing to BioPrint. As of December 31, 2010 the Company was 6.86%-owned by Institut Pasteur de Lille and 4.28%-owned by OTC Asset Management. Cerep SA operates two wholly owned subsidiaries: Cerep Inc, based in the United States and Cerep Drug Discovery Services Co. Ltd, based in China. In our complete report available for purchase the company is compared to: Bioalliance Pharma, Millet Innovation Sa and Exonhit Therapeutics SA.